Innoviva (INVA) Share-based Compensation (2010 - 2026)
Innoviva's (INVA) quarterly Share-based Compensation came in at $101000.0 in Q1 2026, down 95.3% YoY from $2.1 million in Q1 2025, and down 99.56% on a QoQ basis from $22.7 million in Q4 2025.
Innoviva (INVA) Share-based Compensation (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Share-based Compensation data on file, last reported at $101000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 95.3% year-over-year to $101000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 102.73% YoY) and the FY2025 annual result came in at $22.7 million, up 64.09% from the prior year.
- Share-based Compensation slipped to $101000.0 in Q1 2026, from $22.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $22.7 million in Q4 2025 to a low of -$23000.0 in Q1 2023.
- A 5-year average of $3.9 million and a median of $1.2 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 6415.69% — and 2023, when it plunged 110.75%.
- Tracing INVA's Share-based Compensation over 5 years: stood at $8.7 million in 2022, then gained by 9.15% to $9.5 million in 2023, then jumped by 45.72% to $13.9 million in 2024, then surged by 64.09% to $22.7 million in 2025, then slumped by 99.56% to $101000.0 in 2026.
- The last three Share-based Compensation figures came in at $101000.0 (Q1 2026), $22.7 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 4.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.74 Mn |
| Jun 30, 2026 | 4.74 Mn |
| Mar 31, 2026 | 101,000.00 |
| Mar 31, 2026 | 101,000.00 |
| Dec 31, 2025 | 22.74 Mn |
| Dec 31, 2025 | 22.74 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Dec 31, 2024 | 13.86 Mn |
| Dec 31, 2024 | 13.86 Mn |
| Sep 30, 2024 | 211,000.00 |
| Sep 30, 2024 | 211,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Mar 31, 2024 | 404,000.00 |
| Mar 31, 2024 | 404,000.00 |